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Background:  Lung  cancer  nurse  specialists  (LCNS)  are  integral  to the multidisciplinary  clinical  team,  pro-
viding  personalised  physical  and  psycho-social  interventions,  and  care  management  for  people  with
lung  cancer.  The  National  Institute  of  Health  and  Care  Excellence  (NICE)  recommend  that  all  patients
have  access  to a LCNS.  We  conducted  a national  study  assessing  whether  there is variation  in  access  to
and timing  of  LCNS  assessment.
Methods:  The  National  Cancer  Action  Team’s  LCNS  workforce  census  in  England  was  linked  with  patient
and  hospital  Trust  data  from  the  English  National  Lung  Cancer  Audit.  Multivariate  logistic  regression  was
used  to assess  features  associated  with  LCNS  assessment.
Results: 128,124  lung  cancer  patients  were  seen  from  2007  to  2011.  LCNS  assessment  conﬁrmation  was
‘yes’  in 62%,  ‘no’  in 6% and  ‘missing’  in 32%.  Where  (in  clinic  versus  ward)  and  when  (before  versus  after
diagnosis)  patients  were  assessed  by a  LCNS  also  varied.  Older  patients  with  poor  performance  status,
early  cancer  stage,  and  comorbidities  were  less  likely  to  be assessed;  there  was  no difference  with  sex
or socioeconomic  group.  Patients  receiving  any  anti-cancer  treatment  were  more  likely  to  be assessed.
Assessment  was  lower  in  Trusts  with  high  annual  patient  numbers  (odds  ratio  = 0.58,  95% conﬁdence
interval  0.37–0.91)  and where  LCNS  caseload  >  250 (0.69,  0.41–1.16,  although  not statistically  signiﬁcant),
but  increased  where  workload  was  conducted  mostly  by band  8 nurses  (2.22,  1.22–4.02).
Conclusion:  LCNS  assessment  varied  by  patient  and  Trust  features,  which  may  indicate  unmet  need for
some  patients.  The  current  workforce  needs  to  expand  as  well  as  retain  experienced  LCNSs.
©  2016 Published  by Elsevier  Ireland  Ltd.. Introduction
Lung cancer (LC) is the second most common cancer in the
nited Kingdom (UK) with 39,000 new cases annually in Eng-
and [1,2]. Recent National Institute for Health and Care Excellence
NICE) guidelines recommend that every person diagnosed with
C has direct personal access to a Lung Cancer Nurse Specialist
LCNS) in their local hospital who they can meet with and be sup-
orted by throughout the cancer pathway [1,3]. LCNSs are now
∗ Corresponding author.
E-mail address: Aamir.Khakwani@nottingham.ac.uk (A. Khakwani).
ttp://dx.doi.org/10.1016/j.lungcan.2016.03.011
169-5002/© 2016 Published by Elsevier Ireland Ltd.integral to the multidisciplinary team (MDT) within which they
contribute to decisions on their patients’ treatment and care [4].
Previous research has shown the effectiveness of tailored nursing
care and proactive LCNS case management in reducing unnecessary
hospital admissions and doctor consultations, symptom control,
emotional functioning and patient-reported satisfaction for early
and metastatic LC [5–8]. A 2002 randomised control trial by Moore
and colleagues of 203 patients showed that LCNS led follow-up
was also cost-effective when compared with conventional medical
follow-up [8].
Although LC is the second commonest cancer in the UK [9],
LCNSs comprise only 11% of the Cancer Nurse Specialists (CNSs)
in England, compared with breast (20%), colorectal (14%) and urol-
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gy (12%) CNSs [10]. A recent Macmillan report highlighted that
n average, there is one LCNS for every 161 people diagnosed with
C, compared with 117 people diagnosed with breast cancer [11].
ccording to the 2013 National Lung Cancer Audit (NLCA) annual
eport, approximately 80% of all patients are now assessed by a
CNS, but there is variation by Trust and only 30% of LC patients are
ssessed in some Trusts [12].
In this study we linked individual clinical information from the
LCA, the English Hospital Episode Statistics (HES) and Ofﬁce of
ational Statistics (ONS) deaths with the National Cancer Action
eam (NCAT) census on the LCNS workforce. We assessed whether,
hen and where patients are assessed by a LCNS and how clinical,
emographic, socioeconomic status (SES) of patients and National
ealth Services (NHS) Trust characteristics including Trust size,
CNS salary bands and caseload affected their assessment.
. Methods
The NLCA collects key clinical information on all new patients
resenting with a diagnosis of LC in the UK. In this study data
rom the NLCA was linked with HES, which includes all inpatient
dmissions in England, ONS mortality data to provide nationally
egistered dates of death, and NCAT, a census of the entire cancer
pecialist nurse workforce in England which provided details on
he LCNS workforce.
We  included all patients in the NLCA who were ﬁrst seen in
ngland between January 1st, 2007 and December 31st, 2011 across
50 NHS Trusts in England. We  used the latest NCAT census carried
ut in 2011 to map  the workforce of 321 LCNS to NHS Trusts. Trusts
ithout LCNS workforce information from the NCAT (n = 4) were
ropped leaving 146 Trusts for analysis. Patients diagnosed with LC
hrough death certiﬁcate and those with mesothelioma or carcinoid
ere excluded.
The NLCA records whether the patient is assessed by a LCNS (yes,
o), date of assessment, timing of assessment in the cancer path-
ay and location of the ﬁrst assessment. We  categorised the timing
f assessment as before/at diagnosis versus after diagnosis and the
ocation of assessment as in clinic versus ward or other location (i.e.
ome visit, telephone or other). For each of the three variables, where
o information was entered they were separately categorised as
issing.
Age at diagnosis, sex, SES, source of referral to a LC physician,
erformance status (classiﬁed according to WHO  deﬁnition) and
tage of disease (Union for International Cancer Control deﬁnition)
ere identiﬁed from NLCA. Data on active treatment were obtained
rom a combination of the NLCA and HES using methods as previ-
usly described in Ref. [13–15] and categorised as no treatment,
urgery, chemotherapy and radiotherapy, chemotherapy alone or
adiotherapy alone. We  used HES to calculate a patient’s composite
core of co-morbidity (Charlson Index).
We used the NLCA to calculate the number of new LC patients
een annually in each Trust using our established methods [14]. We
stimated each Trust’s caseload per whole time equivalent (WTE)
CNS using the number of new cases ﬁrst seen in 2011 plus the
umber of patients surviving since 2004, divided by the number of
TE LCNSs employed at the Trust. We  assumed that the patients
nitially seen in a particular Trust were equally divided between
he LCNSs employed by that Trust and that patients followed the
C pathway in that same Trust. Using NCAT information on salary
ands of WTE  LCNSs, we assessed the composition of the LCNS team
t each trust. We  also estimated which LCNS salary band conducted
he majority of the work based on WTE  employment at each Trust
e.g. Trust A was categorised at Band 7 if more than 50% of the total
TE  LCNSs were on salary band 7).Fig. 1. Percentage of patients with LCNS assessment by Trust size (annual number
of  new lung cancer patients).
2.1. Statistical analysis
All data analyses were performed using Stata MP12. Initially
we plotted the percentage of patients recorded as having been
assessed by a LCNS by the Trust size (average number of patients
seen annually) and calculated the Pearson’s correlation coefﬁcient
to quantify the relationship. We used multinomial logistic regres-
sion analyses, to estimate the relative risk ratio (RRRs) of being
assessed by a LCNS by patient and NHS Trust features. For all
patients who  had information on having been assessed, we also
performed separate analyses to estimate the RRRs of being assessed
after diagnosis versus before/at diagnosis and being assessed in
clinic versus being assessed on wards. The unadjusted and adjusted
RRR were clustered by NHS Trust to account for the hierarchical
grouping of patient observations. A separate analysis was carried
out for patients with missing data and a sensitivity analyses was
conducted excluding all patients who  died within 30 days of diag-
nosis to account for immortal time bias.
3. Results
There were a total of 128,124 people with LC who were ﬁrst
seen between 1 January 2007 and 31 December 2011, of whom
80,113 (63%) were seen by a LCNS, 7544 (6%) were not seen and
40,467 (31%) had missing data. The proportion of patients assessed
increased over the study period (6216 (31%) in 2007-23,045 (80%) in
2011), mainly driven by a decrease in the missing data. From those
who were assessed, 3809 (5%) had missing information on the tim-
ing of ﬁrst assessment and 8317 (10%) on the location. We observed
a borderline moderate negative correlation between the number of
new cases seen at a Trust and the proportion of patients assessed
by a LCNS (Fig. 1 Pearson’s correlation coefﬁcient = −0.305).
3.1. Who  is assessed by LCNS
Table 1 shows results for being assessed by a LCNS by patient
features. The RRR of being assessed by a LCNS was 6% higher for
men  compared with women, but this association was accounted
for when we  adjusted for other patient features and Trust/LCNS
features (RRR 1.02, 95% CI 0.96–1.07). There was  a clear association
seen with age with patients > 75 years less likely to be assessed.
Patients with worse performance status (PS) and with comorbidi-
ties were also less likely to have been assessed. Patients with LC
stage other than stage IA–IB and stage IV had a higher RRR of being
ng Ca
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MA. Khakwani et al. / Lussessed by a LCNS. The association with stage IV patients was not
een when we carried out a sensitivity analysis and restricted our
nalyses to patients who survived more than 30-days after diag-
able 1
ultinomial logistic regression analysis for patient features and likelihood of being asses
LCNS Assessed 
No n = (7544) % Yes n = (80113) 
Year
2007 675 9 6216 
2008 1368 18 12,235 
2009 1618 21 17,676 
2010  2059 27 20,941 
2011  1824 24 23,045 
Sex
Female 3437 46 35,269 
Male  4107 54 44,844 
Age
<65  1325 18 21,715 
65–75 1961 26 27,118 
>75  4258 56 31,280 
Performance status
0  590 8 14,318 
1 1012 13 24,737 
2  1105 15 15,441 
3  2038 27 12,254 
4  1220 16 3098 
Missing 1579 21 10,265 
Stage
IA-IB  716 10 8779 
IIA-IIB 267 4 4692 
IIIA  448 6 7590 
IIIB  635 8 9322 
IV  3295 44 29,479 
SCLC-Limited 99 1 2933 
SCLC-Extensive 402 5 5792 
Stage  Unknown 1682 22 11,526 
Charlson Index
0  1493 20 26,132 
1 1237 16 16,162 
2–3  1386 18 13,892 
4+  3428 45 23,927 
Townsend Quintile
1 (Most afﬂuent) 1046 14 12,253 
2  1417 19 14,506 
3  1463 19 15,670 
4  1570 21 16,978 
5  (Least afﬂuent) 1824 24 19,240 
Missing 224 3 1466 
Route of referral
Referred from GP 2205 29 40,409 
Emergency Admission 2021 27 9468 
Referred from Consultant 1585 21 16,553 
Following A&E admission 804 11 5310 
Others  425 6 5306 
Missing 504 7 3067 
Treatment
No  treatment 5349 71 27,205 
Surgery 603 8 11,615 
Chemo & radiotherapy 255 3 9626 
Chemo Only 543 7 17,091 
Radiotherapy only 794 11 14,576 
Trust  Size (Annual)
<175 pts 2351 31 30,765 
> = 175 − <265 pts 2195 29 26,507 
>  = 265 pts 2998 40 22,841 
Caseload
<  = 150 cases 1648 22 18,673 
>150  − < = 250 cases 3672 49 43,497 
>  250 cases 2224 29 17,943 ncer 96 (2016) 33–40 35nosis (Supplemental Table 1).There was no difference by SES. We
analysed missing data separately and that the RRR of missing data
compared with patients not assessed revealed that there was no dif-
sed by a LCNS clustered by NHS Trusts (n = 128,124).
Adjusted Relative risk ratioa
% Missing n = (40467) % Yes vs No
8 13,041 32 1
15 10,593 26 0.98 (0.69–1.40)
22 8217 20 1.17 (0.80–1.72)
26 4695 12 1.10 (0.71–1.70)
29 3921 10 1.33 (0.86–2.05)
44 17,428 43 1
56 23,039 57 1.02 (0.96–1.07)
27 10,346 26 1b
34 12,804 32 1.05 (0.96–1.14)
39 17,317 43 0.84 (0.75–0.93)
18 4994 12 1b
31 7208 18 1.14 (0.92–1.41)
19 4802 12 0.97 (0.77–1.23)
15 4903 12 0.63 (0.48–0.81)
4 2038 5 0.34 (0.24–0.46)
13 16,522 41 0.47 (0.34–0.65)
11 3528 9 1b
6 1567 4 1.42 (1.18–1.71)
9 2352 6 1.35 (1.16–1.57)
12 3739 9 1.28 (1.09–1.49)
37 11,191 28 1.10 (0.96–1.27)
4 845 2 1.48 (1.17–1.88)
7 1849 5 1.25 (1.05–1.49)
14 15,396 38 0.89 (0.72–1.09)
33 13,206 33 1b
20 7711 19 0.95 (0.86–1.04)
17 6938 17 0.86 (0.78–0.94)
30 12,612 31 0.71 (0.64–0.80)
15 6509 16 1
18 7785 19 0.89 (0.81–0.99)
20 7977 20 1.00 (0.90–1.11)
21 8639 21 1.04 (0.91–1.20)
24 9121 23 1.06 (0.87–1.29)
2 436 1 0.88 (0.68–1.12)
50 17,590 43 1b
12 4889 12 0.43 (0.35–0.53)
21 8150 20 0.74 (0.63–0.86)
7 3027 7 0.62 (0.48 − 0.82)
7 3492 9 0.87 (0.64 − 1.19)
4 3319 8 0.46 (0.25 − 0.87)
34 18,400 45 1b
15 5605 14 2.04 (1.71–2.44)
12 2578 6 3.93 (3.10–4.98)
21 7828 19 3.42 (2.67–4.38)
18 6056 15 2.57 (2.18–3.04)
38 13,503 33 1b
33 10,165 25 0.97 (0.64–1.49)
29 16,799 42 0.58 (0.37–0.91)
23 6509 16 1
54 24,783 61 1.08 (0.69–1.69)
22 9175 23 0.69 (0.41–1.16)
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Table  1 (Continued)
LCNS Assessed Adjusted Relative risk ratioa
No n = (7544) % Yes n = (80113) % Missing n = (40467) % Yes vs No
LCNS dealing with >50% workc
Majority work 7 band 5986 79 66,942 84 34,746 86 1
Majority work 6 band 1466 19 10,370 13 5069 13 0.71 (0.47–1.07)
Majority work 8 band 92 1 2801 4 652 2 2.22 (1.22–4.02)
LCNS  Bandc
All 7 band 3404 45 35,513 44 16,989 42 1
6,7  & 8 Bands 3619 48 35,808 45 20,347 50 0.96 (0.63–1.45)
7,8  Bands 521 7 8792 11 3131 8 1.59 (0.86–2.92)
Baseline group patients not assessed by LCNS.
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ma Relative risk ratio adjusted for Trust/LCNS feature, year and patient features.
b Signiﬁcant p value for trends/likelihood ratio test (p < 0.05).
c Not Adjusted for other LCNS Band Variable.
erence in being recorded as not seen between patients with stage
A-IB and stage IV. The amount of missing data was similar between
atients from different SES (Supplemental Table 2).
Patients admitted through an emergency route were 57% less
ikely to have been assessed compared with those who were
eferred by a GP. Active treatment was also associated with assess-
ent. Patients who had surgery were twice as likely to be assessed
RRR 2.04), while patients who receive chemotherapy alone or
adiotherapy alone were three times as likely to be assessed (RRR
.42 & 2.51 respectively). However, the strongest association was
een in patients who receive chemotherapy and radiotherapy, who
ere four times as likely to be assessed (RRR 3.93, 95% CI 3.10–4.98).
his association was also present in patients surviving more than
0-days post diagnosis.
Patients ﬁrst seen in a Trust with an annual LC caseload of > = 265
atients were less likely to be assessed compared with smaller
rusts (adjusted RRR 0.58), but we found no association with
ncreasing annual LCNS caseload. There was a higher likelihood of
eing assessed in Trust where the LCNS were on salary band 7 or
 (RRR 1.59), however clustering by NHS Trusts widened the con-
dence interval and made the association non-signiﬁcant. Patients
rst seen in Trusts where the majority of work was done by band 8
urses were twice as likely to have been assessed compared 7 band
rusts (RRR 2.22, 95% CI 1.22–4.02), while trusts where majority of
ork is done by a band 6 LCNS were less likely to have been assessed
RRR 0.71, 95% CI 0.47–1.07).
.2. Point of lung cancer pathway where the patient is ﬁrst
ssessed
Table 2 shows results for the point at which the patient was
rst assessed by a LCNS (n = 80,113). Patients with age > 75 years,
orsening PS and stage, other than stage IV, were less likely to be
ssessed before/at diagnosis but we found no difference with sex.
atients with a comorbidity score of higher than 4 were slightly
ore likely to be assessed before diagnosis than after diagnosis,
hile there was no difference with SES. Patients admitted through
mergency were less likely to have been assessed before diagnosis;
owever those who were referred from another consultant were
6% more likely to have been assessed before receiving their lung
ancer diagnosis. Patients having surgical treatment were almost
wice more likely to have been assessed before/at diagnosis than
fter diagnosis while signiﬁcant association for patients receiving
hemotherapy and radiotherapy was only present in patients sur-
iving 30-days post LC diagnosis (Supplemental Table 1). There was
o association seen with the likelihood of being assessed before/at
iagnosis than after diagnosis with either increasing annual trust
ize or annual WTE  LCNS caseload. LCNS on salary grade 7 or 8 were
ore likely to assess a patient before/at diagnosis than LCNS on alower salary grade while there was  no association seen with trusts
were majority of work is done by either band 6, 7 or 8.
3.3. Where the patient is ﬁrst assessed?
Table 3 presents an overview of unadjusted and adjusted RRR
of where the patients are ﬁrst assessed by a LCNS. Over the years,
the proportion of patients being assessed in clinics versus the pro-
portion being assessed in wards has remained the same. Males and
young people were 9% less likely to have been ﬁrst assessed in a
ward than in a clinic. The strongest association was  seen with PS.
Patients with PS 4 were almost 7 times more likely to have been
ﬁrst seen in a ward than in clinic. People with advanced stage and
comorbidity were also associated with patients being more likely
to have been ﬁrst assessed in the ward. There was no difference in
where the patient is ﬁrst seen by SES, increasing annual WTE  LCNS
caseload or LCNS salary grade/majority work. Patients who receive
any treatment are less likely to have their ﬁrst assessment by a
LCNS in wards than in clinic (RRR 0.48 surgery, 0.47 chemotherapy
and radiotherapy, 0.51 chemotherapy alone and 0.64 radiotherapy
alone).
4. Discussion
Our results demonstrate an increase in the absolute propor-
tion of patients assessed in recent years which is mainly driven
by improvements in data completeness. However, the data reveals
that older patients, with poorer PS, and those admitted through
an emergency route are less likely to be assessed, which was  still
present in patients surviving more than 30-days after diagnosis,
highlighting unmet need. However, it is possible that some patients
are appropriately being referred to supportive and palliative care
nurses, and that the LCNS is instrumental in making this happen.
In contrast to research which indicates a more active approach to
treatment in larger Trust, we  found borderline moderate negative
association between assessment and Trust size.
Overall 32% of patients in our data had missing data. Even though
the ascertainment of this information has improved in recent years,
our results may  be an underestimate of the true proportion of
patients assessed by a LCNS.
As reported previously, there is a strong association between
assessment by a LCNS and active anticancer treatment [4]. We
observed a higher likelihood of being assessed before diagnosis by
a LCNS on a higher salary grade (i.e. 7 or 8) and a higher likelihood
of being assessed where majority of work is done by band 8
nurses. This may  be linked to a better leadership qualities and an
active involvement in MDT  clinics by senior nurses. While patients
diagnosed in a Trust with an annual Trust size of > 265 were less
likely to have been assessed, the effect of increasing caseload per
A. Khakwani et al. / Lung Cancer 96 (2016) 33–40 37
Table  2
Multinomial logistic regression analysis for patient features and at what point in the lung cancer pathway was  the patient assessed clustered by NHS Trusts (n = 80,113).
At what point was patient assessed (n = 80,113) Adjusted Relative risk ratioa
After diagnosis
n = (34149)
% Before/at
diagnosis
n = (42155)
% Missing
n = (3809)
% Before/at
diagnosis vs After
diagnosis
Year
2007 2345 7 3047 7 824 22 1b
2008 4977 15 5861 14 1397 37 0.87 (0.69–1.11)
2009 7968 23 9071 22 637 17 0.83 (0.63–1.08)
2010 9180 27 11,167 26 594 16 0.87 (0.66–1.16)
2011  9679 28 13,009 31 357 9 0.94 (0.71–1.24)
Sex
Female 14,963 44 18,678 44 1628 43 1
Male  19,186 56 23,477 56 2181 57 0.97 (0.95–1.00)
Age
<65  8801 26 11,869 28 1045 27 1
65–75 11,265 33 14,584 35 1269 33 0.98 (0.93–1.02)
>75  14,083 41 15,702 37 1495 39 0.93 (0.88–0.98)
Performance status
0  5236 15 8391 20 691 18 1b
1 9991 29 13,951 33 795 21 0.97 (0.85–1.10)
2  6713 20 8203 19 525 14 0.93 (0.79–1.09)
3  5904 17 5957 14 393 10 0.83 (0.69–1.01)
4  1524 4 1460 3 114 3 0.83 (0.65–1.07)
Missing 4781 14 4193 10 1291 34 0.68 (0.56–0.82)
Stage
IA-IB  3103 9 5308 13 368 10 1b
IIA-IIB 1811 5 2705 6 176 5 0.90 (0.83–0.97)
IIIA  3058 9 4250 10 282 7 0.94 (0.88–1.01)
IIIB  4063 12 4857 12 402 11 0.88 (0.80–0.96)
IV  13,409 39 14,987 36 1083 28 0.84 (0.78–0.90)
SCLC-Limited 1161 3 1692 4 80 2 1.00 (0.90–1.12)
SCLC-Extensive 2496 7 3142 7 154 4 0.91 (0.81–1.02)
Stage Unknown 5048 15 5214 12 1264 33 0.81 (0.71–0.92)
Charlson Index
0  11,281 33 13,586 32 1265 33 1b
1 6799 20 8591 20 772 20 1.09 (1.03–1.15)
2–3  5997 18 7253 17 642 17 1.09 (1.03–1.16)
4+  10,072 29 12,725 30 1130 30 1.31 (1.22–1.41)
Townsend Quintile
1 (Most afﬂuent) 5379 16 6296 15 578 15 1
2  6369 19 7534 18 603 16 1.01 (0.93–1.11)
3  6780 20 8237 20 653 17 1.04 (0.94–1.15)
4  7204 21 8919 21 855 22 1.06 (0.93–1.20)
5  (Least afﬂuent) 7729 23 10,428 25 1083 28 1.20 (1.00–1.43)
Missing 688 2 741 2 37 1 1.07 (0.90–1.29)
Route of Referral
Referred from GP 15,995 47 22,678 54 1736 46 1b
Emergency Admission 4910 14 4144 10 414 11 0.61 (0.52–0.71)
Referred from Consultant 7389 21 8522 20 642 17 0.76 (0.67–0.87)
Following A&E admission 2779 8 2216 5 315 8 0.57 (0.49–0.68)
Others 1954 6 3028 7 324 9 1.11 (0.79 − 1.56)
Missing 1122 3 1567 4 378 10 1.01 (0.73 − 1.38)
Treatment
No  treatment 12,801 37 12,906 31 1498 39 1b
Surgery 3565 10 7401 18 649 17 1.74 (1.54–1.96)
Chemo & radiotherapy 4119 12 5222 12 285 7 1.10 (0.95–1.27)
Chemo Only 7203 21 9126 22 762 20 1.12 (1.03–1.22)
Radiotherapy only 6461 19 7500 18 615 16 1.07 (0.98–1.17)
Trust  Size (Annual)
<175 pts 13,240 39 16,461 39 1064 28 1b
> = 175 − <265 pts 10,849 32 14,072 33 1586 42 1.02 (0.67–1.55)
>  = 265 pts 10,060 29 11,622 28 1159 30 0.85 (0.58–1.23)
Caseload
<  = 150 cases 7860 23 10,450 25 363 10 1
>150  − < = 250 cases 18,637 55 22,109 52 2751 72 0.92 (0.58–1.45)
>250  cases 7652 22 9596 23 695 18 1.02 (0.60–1.73)
LCNS  dealing with
>50% workc
Majority work 7 band 29,245 86 35,128 83 2569 67 1
Majority work 6 band 3842 11 5674 13 854 22 1.24 (0.75–2.05)
Majority work 8 band 1062 3 1353 3 386 10 0.99 (0.31–3.12)
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Table  2 (Continued)
At what point was  patient assessed (n = 80,113) Adjusted Relative risk ratioa
After diagnosis n = (34149) % Before/at diagnosis n = (42155) % Missing n = (3809) % Before/at diagnosis vs After diagnosis
LCNS Band
All 7 band 16,442 48 17,775 42 1296 34 1
6,7  & 8 Bands 15,121 44 18664 44 2023 53 1.17 (0.82–1.66)
7,8  Bands 2586 8 5716 14 490 13 2.09 (1.18 –3.71)
Baseline group patients assessed after diagnosis.
T
Ma Relative risk ratio adjusted for Trust/LCNS feature, year and patient features.
b Signiﬁcant p value for trends/likelihood ratio test (p < 0.05).
c Not Adjusted for other LCNS Band Variable.able 3
ultinomial logistic regression analysis for patient features and where the patient was  ﬁ
Where was  the patient ﬁrst assessed (n = 80,113)
In Clinic
n = (49065)
% In Ward
n = (15792)
% Others (in
tele/home
n = (6939)
Year
2007 3114 6 1074 7 667 
2008 7111 14 2527 16 788 
2009  11,216 23 3485 23 1450 
2010  13,316 27 4074 26 2019 
2011  14,308 29 4432 28 2015 
Sex
Female 21,301 43 7149 45 3136 
Male 27,764 57 8643 55 3803 
Age
<  65 13,644 28 3874 25 1969 
65–75  17,071 35 4851 31 2392 
>  75 18,350 37 7067 45 2578 
Performance status
0  10,651 22 1060 7 1235 
1  17,356 35 2911 18 2322 
2  9414 19 3418 22 1231 
3  5506 11 4730 30 819 
4  758 2 1853 12 177 
Missing 5380 11 1820 12 1155 
Stage
IA-IB  6192 13 681 4 961 
IIA-IIB 3319 7 478 3 444 
IIIA  5318 11 885 6 671 
IIIB  6133 12 1548 10 791 
IV  16,611 34 7896 50 2284 
SCLC-Limited 2000 4 413 3 253 
SCLC-Extensive 3283 7 1609 10 428 
Stage  Unknown 6209 13 2282 14 1107 
Charlson Index
0 18,384 37 2668 17 2289 
1  10,647 22 2381 15 1493 
2–3  8940 18 2293 15 1252 
4+  11094 23 8450 54 1905 
Townsend Quintile
1 (Most afﬂuent) 7611 16 2258 14 1263 
2  8972 18 2678 17 1458 
3  9696 20 2989 19 1486 
4  10,462 21 3396 21 1376 
5  (Least afﬂuent) 11,548 24 4014 25 1244 
Missing 776 2 457 3 112 
Route  of Referral
Referred from GP 29257 60 3272 21 3845 
pEmergency
Admission
3050 6 5073 32 682 
Referred from
Consultant
9961 20 3679 23 1438 rst assessed by a LCNS clustered by NHS Trust (n = 80,113).
Adjusted Relative risk ratioa
c
)
% Missing
n = (8317)
% In Ward vs
In Clinic
Other vs In
Clinic
10 1361 16 1b 1b
11 1809 22 1.00 (0.82–1.21) 0.49 (0.30–0.81)
21 1325 16 0.95 (0.75–1.20) 0.60 (0.36–0.99)
29 1532 18 0.86 (0.70–1.06) 0.73 (0.44–1.22)
29 2290 28 0.89 (0.70–1.13) 0.68 (0.42–1.11)
45 3683 44 1b 1
55 4634 56 0.91 (0.87–0.95) 0.91 (0.87–0.96)
28 2228 27 1 1
34 2804 34 0.85 (0.81–0.90) 0.92 (0.86–1.00)
37 3285 39 0.81 (0.75–0.87) 0.86 (0.79–0.94)
18 1372 16 1b 1
33 2148 26 1.30 (1.12–1.49) 1.16 (0.98–1.36)
18 1378 17 1.96 (1.67–2.29) 1.12 (0.96–1.32)
12 1199 14 3.36 (2.81–4.02) 1.26 (1.04–1.52)
3 310 4 7.22 (5.75–9.07) 1.94 (1.42–2.64)
17 1910 23 1.87 (1.56–2.24) 1.66 (1.35–2.06)
14 945 11 1b 1
6 451 5 1.32 (1.13–1.54) 0.86 (0.75–1.00)
10 716 9 1.43 (1.25–1.64) 0.81 (0.70–0.94)
11 850 10 1.97 (1.73–2.25) 0.85 (0.73–0.98)
33 2688 32 2.33 (2.04–2.67) 0.83 (0.72–0.95)
4 267 3 2.15 (1.81–2.55) 0.83 (0.71–0.98)
6 472 6 2.84 (2.40–3.35) 0.80 (0.68–0.95)
16 1928 23 2.10 (1.79–2.45) 1.00 (0.79–1.27)
33 2791 34 1b 1
22 1641 20 1.21 (1.12–1.30) 1.10 (1.01–1.21)
18 1407 17 1.18 (1.09–1.29) 1.10 (1.00–1.20)
27 2478 30 2.46 (2.27–2.66) 1.32 (1.18–1.46)
18 1121 13 1 1
21 1398 17 1.00 (0.92–1.09) 0.99 (0.89–1.11)
21 1499 18 0.99 (0.90–1.08) 0.94 (0.83–1.07)
20 1744 21 0.96 (0.86–1.06) 0.81 (0.69–0.95)
18 2434 29 0.97 (0.85–1.11) 0.67 (0.54–0.85)
2 121 1 1.30 (1.09–1.56) 0.81 (0.63–1.05)
55 4035 49 1b 1
10 663 8 8.48 (6.65–10.8) 1.52 (1.22–1.88)
21 1475 18 2.51 (2.12–2.97) 1.03 (0.89–1.19)
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Table  3 (Continued)
Where was the patient ﬁrst assessed (n = 80,113) Adjusted Relative risk ratioa
In Clinic
n  = (49065)
% In Ward
n = (15792)
% Others (inc
tele/home)
n = (6939)
% Missing
n = (8317)
% In Ward vs
In Clinic
Other vs In
Clinic
pFollowing
A&E
admission
1991 4 2427 15 382 6 510 6 6.72 (5.50–8.20) 1.41 (1.14–1.74)
Others 3401 7 945 6 357 5 603 7 2.01 (1.54–2.63) 0.74 (0.50–1.09)
Missing 1405 3 396 3 235 3 1031 12 2.07 (1.29–3.31) 1.32 (0.79–2.23)
Treatment
No  treatment 13,295 27 8997 57 2017 29 2896 35 1b 1
Surgery 8285 17 769 5 1223 18 1338 16 0.48 (0.42–0.57) 1.05 (0.90–1.22)
Chemo & radiotherapy 6728 14 1131 7 913 13 854 10 0.47 (0.41–0.55) 1.00 (0.83–1.19)
Chemo Only 11,669 24 2285 14 1466 21 1671 20 0.51 (0.45–0.57) 0.90 (0.79–1.03)
Radiotherapy only 9088 19 2610 17 1320 19 1558 19 0.64 (0.58–0.70) 1.03 (0.92–1.14)
Trust  Size (Annual)
<175 pts 19,117 39 6840 43 2873 41 1935 23 1b 1
>  = 175 − <265 pts 15,683 32 5307 34 2788 40 2729 33 0.96 (0.76–1.21) 1.20 (0.75–1.92)
>  = 265 pts 14,265 29 3645 23 1278 18 3653 44 0.76 (0.58–1.00) 0.61 (0.40–0.94)
Caseload
<  = 150 cases 11,557 24 4313 27 1507 22 1296 16 1 1
>150  − < = 250 cases 25,667 52 7518 48 3899 56 6413 77 0.88 (0.69–1.13) 1.09 (0.68–1.73)
>250  cases 11,841 24 3961 25 1533 22 608 7 1.03 (0.75–1.42) 0.90 (0.51–1.57)
LCNS  dealing
with > 50%
workc
Majority work 7 band 42,443 87 13,476 85 6148 89 4875 59 1 1
Majority work 6 band 5130 10 1791 11 608 9 2841 34 1.30 (0.87–1.94) 0.97 (0.49–1.92)
Majority work 8 band 1492 3 525 3 183 3 601 7 1.04 (0.80–1.35) 0.80 (0.41–1.55)
LCNS  Band
All 7 band 22,527 46 7643 48 3330 48 2013 24 1 1
6,7  & 8 Bands 21,097 43 6417 41 3065 44 5229 63 0.90 (0.72–1.14) 0.96 (0.61–1.53)
7,8  Bands 5441 11 1732 11 544 8 1075 13 0.95 (0.74–1.22) 0.69 (0.41–1.15)
Baseline group patients assessed in clinic.
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sa Relative risk ratio adjusted for Trust/LCNS feature, year and patient features.
b Signiﬁcant p value for trends/likelihood ratio test (p < 0.05).
c Not Adjusted for other LCNS Band Variable.
TE  LCNS on the likelihood of being assessed was not present
ven when adjusted for several patient and Trust features. This
ay  be due to differences in access to a LCNS, which were not
xamined in this study.
This study uses a large representative dataset reﬂects real
ife LC care in England. Although the data entry in the NLCA is
on-mandatory, the linked database has been validated [16]. The
scertainment of cases and data completeness has improved annu-
lly with recent audit result reports ascertainment closer to 100%
17]. We  had a large proportion of patients with missing data on
CNS input; but the decreasing missing information in recent years
ssociated with no change in the proportion of assessed vs not
ssessed in the database suggests that this was not deliberate (Sup-
lemental Table 2). This is the ﬁrst time a snapshot of the LCNS
orkforce together with the patient level data was  used to create
n approximate patient caseload per WTE  LCNS. Although we used
he most recent data from the NCAT, the number of employed LCNS
as remained relatively stable since 2007 (301 total LCNS in 2010
 321 in 2011). Our results could be inﬂuenced by bias as patients
ith aggressive disease and short survival time may  not have the
pportunity to be assessed, however we conducted a sensitivity
nalysis limiting to all those patients who have survived for more
han 30 days after diagnosis and observed the same association
Supplemental Table 1). It could be argued for some patients opt-
ng for palliative treatment, a palliative care specialist nurse would
e more effective at attending to patient’s needs, but we believe
hat the skills and expertise of the LCNS are complementary and
hould still be available.We created two  variables to measure the effectiveness of LCNS
based on their salary grade and the amount of work performed
by them and observed a relationship of patients being assessed
more and before diagnosis with Trusts where more senior nurses on
higher salary bands are hired. With recent downgrading of nurses
to band 6, our study highlights evidence of hiring more experi-
enced nurses. It is very likely that many patients during the course
of their treatment change nurses (for e.g. from LCNS to specialist
oncology nurse) and not all patients visit a LCNS each year sur-
vived after their diagnosis, however we believe that the number
would be sufﬁciently small because of the poor survival rates [18]
of LC and majority of the caseload for each LCNS comprised of new
patients. Additionally, the surviving patients can still contact or can
be referred to a LCNS from other CNSs.
We assumed that being assessed in a clinic represented best
practice as it signiﬁed patients contact with the LCNS during the
initial LC pathways. This may  not be the true for patients suffering
from aggressive LC where they are ﬁrst presented in emergency
rather than visit to their GP. This would not make much difference
as only 13% of the total LC population are referred to a lung physi-
cian in emergency, while around 50% are referred from GPs and
other consultants [14,19,20].
The NICE guidelines have stated that every patient diagnosed
with LC should have an access to a LCNS [1] while the NLCA audit
suggesting that 80% of patients in each Trust should be assessed by
a LCNS [12] and our results do provide evidence that most Trusts are
now achieving this benchmark. In addition, there is also the pres-
ence of variation in caseload per WTE  LCNS which is also observed
in the NLCA annual audit reports [12,17].
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collaborative approach—Improvement stories from lung cancer teams.0 A. Khakwani et al. / Lu
We  used a combination of database and survey to plot LCNS
ctivities in NHS Trusts in England, and found that contact with
CNS was associated with increased likelihood of having received
hemotherapy, radiotherapy and surgery. These results, except
or surgery, are similar to results presented by Beckett et al. [4]
ho analysed patients in the NLCA in 2009. However, due to the
etrospective analysis nature of the study and limited data on deter-
ining at which point in the LC pathway these patients were
ssessed, it is difﬁcult to establish temporal relationship between
eing assessed and receiving anti-cancer therapy. Our results indi-
ate that Trusts with low annual patient Trust size or with low per
TE LCNS caseload were more likely to assess patients which is
imilar to the Royal College of Physicians report [21], which found
hat multidisciplinary teams with low caseload per LCNS more
ikely to meet targets for outcomes.
. Conclusion
LCNS provide a valued service for patients suffering from LC
owever we found wide variations between patient features,
nnual Trust workload, LCNS caseload and who are assessed by a
CNS in between Trusts across England suggesting an unmet need
f some patients with LC. To meet the needs of all people with LC
nd the clear targets set out by NICE, we need to expand the current
CNS workforce and ensure that we retain experienced nurses as
CNS are an integral part of the LC team and provide help to people
ith LC.
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